Cost-Minimization Analysis of Metformin and Acarbose in Treatment of Type 2 Diabetes

Value in Health Regional Issues

Volumn 6, Issue , 2015, Pages 84-88

  Gu, Shuyan ^a   Tang, Zhiliu ^b   Shi, Lizheng ^c   Sawhney, Monika ^d   Hu, Huimei ^a   Dong, Hengjin ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BRISTOL MYERS SQUIBB   (United States)

^c TULANE UNIVERSITY   (United States)

^d MARSHALL UNIVERSITY   (United States)

Author keywords

Acarbose; Cost minimization; Metformin; Type 2 diabetes

Indexed keywords

ACARBOSE; METFORMIN;

ARTICLE; CHINA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

EID: 84929079565     PISSN: 22121099     EISSN: 22121102     Source Type: Journal    
DOI: 10.1016/j.vhri.2015.03.012     Document Type: Article

References (53)

1. 1996-2000 National Diabetes Prevention Program. Chin J Prev Control Chronic Non-Commun Dis 1996, 4:49-50.
2. Xu Y., Wang L.M., He J., et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013, 310:948-959.
3. Hu S.L., Liu G.E., Xu Z.R., et al. Current status of epidemic and economic burden of diabetes mellitus in China. Chin Health Econ 2008, 27:5-8.
4. International Diabetes Federation. Types of diabetes. Available from: [Accessed March 10, 2014]. http://www.idf.org/about-diabetes.
5. Wang W., McGreevey W.P., Fu C., et al. Type 2 diabetes mellitus in China: a preventable economic burden. Am J Manag Care 2009, 15:593-601.
6. Standards of medical care in diabetes--2013. Diabetes Care 2013, 36(Suppl 1.):S11-S66. American Diabetes Association.
7. Chinese guideline for type 2 diabetes prevention (2013). Chin J Diabetes 2014, 22:2-42. Chinese Diabetes Society.
8. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012, 35:731-737. Diabetes Prevention Program Research Group.
9. Ji L., Lu J., Weng J., et al. China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. J Diabetes 2015, 7:166-173.
10. Zhu Q., Tong Y., Wu T., et al. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis. Clin Ther 2013, 35:880-899.
11. Gu SY, Xu XC, Shi LZ, et al. Cost minimization analysis of clinical option scenarios for metformin and acarbose in treatment of type 2 diabetes: based on direct and indirect treatment comparison results: ISPOR 6th Asia-Pacific Conference. Available from: [Accessed March 14, 2015]. http://www.ispor.org/research_pdfs/47/pdffiles/PDB27.pdf.
12. Chen L.L., Zheng J. Comparison of the effect of acarbose, metformin and glipizide on newly diagnosed young type 2 diabetic patients. Chin J Endocrinol Metab 2004, 20:449-450.
13. Chou W.Z. Clinical observation of type 2 diabetes treatment with acarbose. Mod J Integ Tradit Chin West Med 2013, 22:2877-2879.
14. Hong F. The analysis of efficacy and medication of several drugs to treat type 2 diabetes. China Pract Med 2011, 6:172-173.
15. Tang Y., Chen F.M. The analysis of efficacy and side effects of acarbose and metformin to treat type 2 diabetes. Natl Med Front China 2013, 8(18):36.
16. Wang H.B., Deng X.C., Feng Y.T. Clinical observation of diabetes II treatment with acarbose and metformin. Mod Hosp 2005, 5:42-43.
17. Yang H.L. Observation of clinical effect on acarbose to treat type 2 diabetes. Med Recapitulate 2009, 15:3196-3197.
18. Zhang M.H. Treatment effect of metformin and acarbose in patients with type 2 diabetic insulin resistance. Jilin Med J 2011, 32:3682-3683.
19. Zhu Z.L., Qiu X.C., Zhu H.P., et al. Application of acarbose combined with metformin in treatment of newly diagnosed type 2 diabetes patients. Heilongjiang Med J 2011, 24:223-225.
20. National Development and Reform Commission Price [2010]. No. 2829: notice on reducing the highest retail prices of several drugs such as ceftriaxone. Available from: [Accessed May 30, 2014]. http://www.ndrc.gov.cn/zcfb/zcfbtz/201011/t20101130_383648.html.
21. Notice on publicity for the use of a few drug species (second batch) that are not included in the procurement catalog of essential drugs in medical institutions above secondary in 2013. Available from: [Accessed May 30, 2014]. http://ypcgzx.jswst.gov.cn/zxxx/6370.html.
22. National Development and Reform Commission Price [2011]. No. 1670: notice on adjusting the prices and related issues of drugs such as hormone, regulates endocrine and nervous system drugs. Available from: [Accessed May 30, 2014]. http://www.ndrc.gov.cn/zcfb/zcfbtz/201108/t20110805_427311.html.
23. Centralized procurement of essential drugs in Beijing in 2012. Available from: [Accessed May 30, 2014]. http://www.bjmbc.org.cn/index/index.aspx.
24. Glucophage® (metformin hydrochloride tablets) Glucophage® XR (metformin hydrochloride extended-release tablets) description. Available from: [Accessed March 20, 2014]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdf.
25. Precose® (acarbose tablets) description. Available from: [Accessed March 20, 2014]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020482s025lbl.pdf.
26. Saenz A., Fernandez-Esteban I., Mataix A., et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005, (3):CD002966.
27. China guidelines for pharmacoeconomic evaluations. China J Pharm Econ 2011, 3:7-48. Chinese Group for Pharmacoeconomic Evaluations Guidelines.
28. Diabetes treatments. 2014. Available from: [Accessed February 25, 2014]. http://media.empr.com/documents/2/endo_dt_2pt-5_1127.pdf.
29. Rodier M., Richard J.L., Monnier L., et al. Effect of long term acarbose (Bay g 5421) therapy on metabolic control of non insulin dependent (type II) diabetes mellitus. Diabetes Metab 1988, 14:12-14.
30. Ahr H.J., Boberg M., Krause H.P., et al. Pharmacokinetics of acarbose, part I: absorption, concentration in plasma, metabolism and excretion after single administration of [14C] acarbose to rats, dogs and man. Arzneimittelforschung 1989, 39:1254-1260.
31. National Health and Family Planning Commission of the People's Republic of China. On the issuance of "Administration measures for the national essential medicines list (Provisional)" notice. 2009. Available from: [Accessed March 10, 2014]. http://www.sda.gov.cn/WS01/CL0056/40754.html.
32. The Central People's Government of the People's Republic of China. The work program for the adjustment of national basic medical insurance, work-related injury insurance and maternity insurance drug lists. 2009. Available from: [Accessed March 10, 2014]. http://www.gov.cn/gzdt/2009-07/31/content_1380699.htm.
33. The Central People's Government of the People's Republic of China. Opinions on deepening the medical and health system reform. 2009. Available from: [Accessed March 10, 2014]. http://www.sda.gov.cn/WS01/CL0611/41193_5.html.
34. National Development and Reform Commission. The measures for the administration of drug price (exposure draft). 2010. Available from: [Accessed March 10, 2014]. http://www.ypzbxx.com/thread-12092-1-1.html.
35. Bu Y.S., Qu S., Liu W., et al. Economic evaluation of two different oral drug treatments for type 2 diabetes. Chin J Hosp Pharm 2006, 26:319-320.
36. Shen W.X., Zhang B.S. Cost-effectiveness analysis of four treatment therapies for type 2 diabetes. China Pharm 2011, 22:4579-4581.
37. Guo S.Y., Tan M.X. Cost-effectiveness analysis of drugs in treatment of type 2 diabetes mellitus. Med Health Mod 2009, 25:1145-1147.
38. Lin L., Ge Y.P. Cost-effectiveness analysis for three common treatments for type 2 diabetes. Med Inf 2010, 23:3154-3156.
39. Ji B., Liu S. The cost-effectiveness analysis of oral hypoglycemic drugs in the treatment of type 2 diabetes mellitus. Chin J Clin Rational Drug Use 2009, 2:27-28.
40. Zhang Q.X., Liu Y.X. Cost-effectiveness analysis of three drug treatments for type 2 diabetes mellitus. Hebei Med J 2014, 36:2049-2051.
41. Wu S.J., Wu W. Cost-effectiveness analysis of acarbose and metformin for the treatment of type 2 diabetes mellitus. Acta Academiae Medicinae Xuzhou 2014, 34:203-205.
42. Wang W.D. The cost-effectiveness analysis of five medications for type 2 diabetes. J Pract Med Tech 2006, 13:1864-1865.
43. Cai X.L., Huang L., Zhao R., et al. Analysis on pharmaceutical economics of different oral antidiabetic drugs for treating type-2 diabetes mellitus. China Pharm 2009, 18:40-41.
44. Zheng Y.Y. Cost-effectiveness analysis of 3 different drugs in the treatment of type 2 diabetes mellitus. China Pharm 2005, 16:994-995.
45. Zhou X., Yao Z.J., Tian X.Y. The cost-effectiveness analysis of three treatments for type 2 diabetes. Pract Clin Med 2006, 7:18-19. 21.
46. Xu W.Z. To explore the therapeutic regimen for type 2 diabetes mellitus. Med Frontier 2013, 21:211-212.
47. He Z.G., Ding Q.F., Jin L. Comparison of cost-minimization analyses between metformin and acarbose combined with insulin in treating type 2 diabetes mellitus. China Pharm 2005, 16:750-751.
48. Wang J.Y. Cost-effectiveness analysis of commonly used hypoglycemic drug combination regimens for the treatment of type 2 diabetes. For All Health 2013, 07:14.
49. Xue X., Gao J.R., Xia L.Z., et al. Cost-effectiveness analysis of glimepiride combined with different drugs in treatment of type 2 diabetes mellitus. AnHui Med Pharm J 2014, 18:441-443.
50. Sun K. Comparison of the efficacy and costs of different treatments of type 2 diabetes. Health Must-Read Magazine 2012, 11:209-210.
51. Lu Z.Q., Ding W. Economic evaluation of metformin hydrochloride and acarbose on treating type 2 diabetes mellitus. Drug Eval 2013, 10:22-33.
52. Hu Y., Chen S.Y., Wang J.Y. Cost-effective analysis of preventive treatment on diabetes. Chin J Epidemiol 2004, 25:431-434.
53. Zhang H.R. Comparison of efficacy and costs of acarbose and metformin hydrochloride in treating for patients with impaired glucose tolerance. Chin Community Doctors 2013, 15:144-145.